{
    "relation": [
        [
            "",
            "Arm A (ZDV Only)",
            "ARM B (ZDV + NVP)",
            "ARM C (ZDV + 3TC + NFV)"
        ],
        [
            "Description",
            "Standard of care ( Zidovudine only). 12 mg PO BID if BW>2000 grams ; 8 mg PO BID if BW",
            "Standard of care (Zidovudine) plus Nevirapine (NVP) NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose : 12 mg PO per dose if BW > 2000 grams, 8 mg PO per dose if BW < 2000 grams",
            "Standard of Care (Zidovudine) plus 2 weeks of Epivir (3TC) and Nelfinavir (NFV) 3TC, given for 2 weeks: 6 mg po bid if BW > 2000 grams 4 mg po bid if BW < 2000 grams AND NFV, given for 2 weeks: 200 mg po bid if BW > 3000 grams 150 mg po bid if BW > 2,000 - 3000 grams 100 mg PO BID if BW < 2000 grams"
        ]
    ],
    "pageTitle": "Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00099359?sect=X0125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042981460.12/warc/CC-MAIN-20150728002301-00058-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 848612975,
    "recordOffset": 848599825,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{24158=6 mg po bid if BW > 2000 grams 4 mg po bid if BW < 2000 grams AND, 4939=200 mg po bid if BW > 3000 grams 150 mg po bid if BW > 2,000 \u2013 3000 grams 100 mg PO BID if BW < 2000 grams, 24354=200 mg po bid if BW > 3000 grams 150 mg po bid if BW > 2,000 - 3000 grams 100 mg PO BID if BW < 2000 grams, 4639=Standard of Care (Zidovudine) plus 2 weeks of Epivir (3TC) and Nelfinavir (NFV) 3TC, given for 2 weeks: 6 mg po bid if BW > 2000 grams 4 mg po bid if BW < 2000 grams AND, 4295=12 mg PO per dose if BW > 2000 grams, 8 mg PO per dose if BW < 2000 grams, 23264=12 mg PO BID if birthweight (BW) > 2000 grams 8 mg PO BID if BW < 2000 grams}",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details The first subject was enrolled on 02/27/2004 and the study ended 02/28/2011. A total of 17 sites in Brazil, South Africa, Argentina and the U.S. participated in the study. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Zidovudine Drug: Nevirapine (NVP) Drug: Epivir (3TC) Drug: Nelfinavir (NFV) Interventions: Disease Transmission, Vertical Vertical Human Immunodeficiency Virus Transmission HIV Infections Conditions: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Prevention Study Design:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Arm A (ZDV Only) \u00a0 \u00a0 ARM B (ZDV + NVP) \u00a0 \u00a0 ARM C (ZDV + 3TC + NFV) \u00a0 STARTED \u00a0 \u00a0 581 \u00a0 \u00a0 580 \u00a0 \u00a0 574 \u00a0 COMPLETED \u00a0 \u00a0 527 \u00a0 \u00a0 515 \u00a0 \u00a0 506 \u00a0 NOT COMPLETED \u00a0 \u00a0 54 \u00a0 \u00a0 65 \u00a0 \u00a0 68 \u00a0 Death \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 11 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 15 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 17 \u00a0 Withdrawal by Subject \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}